Mustang Bio (Nasdaq:MBIO) - Hisse Senedi Fiyatı, Haberler ve Analizler

MBIO Stoklara Genel Bakış

MBIO temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	1/6
Temettüler	0/6

Ödüller

Kazançlar son 5 yılda yılda 1.5% oranında arttı

Risk Analizi

Negatif hissedar öz sermayesi

1 yıldan az nakit akışı var

Anlamlı bir piyasa değeri yok ( $10M )

Hissedarlar geçen yıl önemli ölçüde sulandırıldı

+ 4 daha fazla risk

Mustang Bio, Inc. Rakipler

Imunon

NasdaqCM:IMNN

US$12.0m

Senti Biosciences

NasdaqCM:SNTI

US$9.7m

BioRestorative Therapies

NasdaqCM:BRTX

US$10.4m

Oncotelic Therapeutics

OTCPK:OTLC

US$12.9m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Mustang Bio
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$0.19
52 Haftanın En Yüksek Seviyesi	US$1.66
52 Haftanın En Düşük Seviyesi	US$0.13
Beta	1.92
11 Aylık Değişim	-37.09%
3 Aylık Değişim	-37.21%
1 Yıllık Değişim	-86.62%
33 Yıllık Değişim	-99.32%
5 Yıllık Değişim	-99.67%
Halka arzdan bu yana değişim	-99.87%

Son Haberler & Güncellemeler

Recent updates

Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers

Jun 11

Checking Back In On Mustang Bio

May 26

FDA accepts Mustang Bio's MB-106 application in cancer

May 10

Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation

Mar 22

What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?

Feb 23

Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price

Jan 28

Hissedar Getirileri

	MBIO	US Biotechs	US Pazar
7D	-9.1%	4.3%	1.6%
1Y	-86.6%	18.8%	32.3%

Getiri vs. Endüstri: MBIO geçen yıl % 18.8 oranında getiri sağlayan US Biotechs sektörünün gerisinde kaldı.

Getiri vs Piyasa: MBIO geçen yıl % 32.3 oranında getiri sağlayan US Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is MBIO's price volatile compared to industry and market?
MBIO volatility
MBIO Average Weekly Movement	13.4%
Biotechs Industry Average Movement	9.8%
Market Average Movement	6.3%
10% most volatile stocks in US Market	16.2%
10% least volatile stocks in US Market	3.1%

İstikrarlı Hisse Senedi Fiyatı: MBIO hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.

Zaman İçindeki Volatilite: MBIO 'nin haftalık oynaklığı son bir yılda 69% dan 13% a düştü, ancak hâlâ US hisselerinin %75'inden yüksek.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	80	Manny Litchman	www.mustangbio.com

Klinik aşamada bir biyofarmasötik şirketi olan Mustang Bio, Inc. hücre ve gen tedavilerindeki tıbbi atılımları hematolojik kanserler, solid tümörler ve nadir genetik hastalıklar için potansiyel tedavilere dönüştürmeye odaklanmaktadır. Boru hattı, nadir genetik bozukluklar için gen terapisi programlarına, hematolojik maligniteler için kimerik antijen reseptörü (CAR) mühendislik T hücresi (CAR T) tedavilerine ve solid tümörler için CAR T tedavilerine odaklanmaktadır. Şirket, etkilenen hastaların tedavi olmaksızın bebeklikten öteye yaşayamadığı nadir bir genetik bağışıklık sistemi durumu olan X'e bağlı şiddetli kombine immün yetmezlik için bir gen terapisi programı olan MB-117 ve MB-217'yi geliştirmektedir.

Mustang Bio, Inc. Temel Bilgiler Özeti

Mustang Bio'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
MBIO temel i̇stati̇sti̇kler
Piyasa değeri	US$9.54m
Kazançlar(TTM)	-US$23.42m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.4x

F/K Oranı

MBIO aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
MBIO gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$23.42m
Kazançlar	-US$23.42m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.49
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

MBIO uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

MBIO Stoklara Genel Bakış

Ödüller

Risk Analizi

Mustang Bio, Inc. Rakipler

NasdaqCM:IMNN

US$12.0m

NasdaqCM:SNTI

US$9.7m

NasdaqCM:BRTX

US$10.4m

OTCPK:OTLC

US$12.9m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Nasdaq Hearings Panel Grants Mustang Bio's Request for an Extension Through January 31, 2025, to Demonstrate Compliance with the Bid Price Rule, and Through February 18, 2025, to Demonstrate Compliance with the Equity Rule

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

New major risk - Market cap size

New major risk - Financial position

New major risk - Market cap size

Recent updates

Nasdaq Hearings Panel Grants Mustang Bio's Request for an Extension Through January 31, 2025, to Demonstrate Compliance with the Bid Price Rule, and Through February 18, 2025, to Demonstrate Compliance with the Equity Rule

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

New major risk - Market cap size

New major risk - Financial position

New major risk - Market cap size

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $2.51299 million.

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $5.6 million.

Mustang Bio, Inc. Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of Mb-106, Cd20-Targeted Autologous Car-T Therapy

New major risk - Shareholder dilution

Mustang Bio Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Price target decreased by 43% to US$10.00

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $3.998428 million.

New minor risk - Share price stability

Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mustang Bio Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)(1)

New major risk - Market cap size

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $10.5 million.

New major risk - Financial position

Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma

Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer

Price target decreased by 29% to US$13.00

Mustang Bio, Inc. announced that it has received $4.742942 million in funding

New minor risk - Share price stability

New major risk - Revenue and earnings growth

Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-109, A Novel Combination of MB-101 (IL13RA2-Targeted Car-T Cell Therapy) and MB-108 (HSV-1 Oncolytic Virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Mustang Bio, Inc. Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

uBriGene (Boston) Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc.

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

Consensus EPS estimates upgraded to US$5.61 loss

Price target decreased by 35% to US$40.75

Consensus EPS estimates fall by 286%

Price target increased by 20% to US$75.00

uBriGene (Boston) Biosciences Inc. entered into asset purchase agreement to acquire Worcester manufacturing facility of Mustang Bio, Inc. for $11 million.

Mustang Bio, Inc. Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Price target decreased to US$5.00

Insufficient new directors

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of Mb-106, A First-In-Class Cd20-Targeted, Autologous Car T Cell Therapy to Treat B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio: This Horse May Gallop Still

Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat Rag1 Severe Combined Immunodeficiency

Mustang Bio, Inc. Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

Mustang Bio Receives Letter from the Listing Qualifications Staff of Nasdaq

Mustang Bio, Inc. Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

Price target decreased to US$7.40

Mustang Bio, Inc. Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

Mustang Bio, Inc. Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

Mustang Bio: The Market Is Missing This Opportunity

Mustang Bio, Inc., Annual General Meeting, Jun 21, 2022

Insufficient new directors

Mustang Bio Inc. Announces Updated Interim Phase 1/2 Data for Mb-106, Cd20-Targeted Car T Therapy, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Mustang Bio, Inc. Announces Phase 1 Clinical Trial Combining MB-101 and MB-108 for the Treatment of Glioblastoma

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients

Price target decreased to US$8.40

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?

Price target decreased to US$9.80

Mustang Bio Announces MB-101 (IL13Ra2-targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences